Formulary assessment tool: tirbanibulin (Klisyri)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The formulary assessment tool for tirbanibulin (Klisyri) can be found here.
New Drug Evaluation: Estradiol / progesterone (Bijuve®) for hormone replacement therapy in postmenopausal women
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
The new drug evaluation for estradiol / progesterone (Bijuve®) can be found here.
Prescribing support workplan
This workplan is updated monthly and includes topics in active development.
- To suggest a topic or enquire about anything on this workplan, please email us at nuth.nyrdtc.rxsupp@nhs.net.
- To view a list of recently published items, visit the recent publications page of our website.
- See the last page of the workplan for descriptions of each type of publication, and anticipated publication frequency.
Formulary assessment tool: testosterone 2% gel (Tostran) in post-menopausal women
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The Formulary assessment tool for testosterone 2% gel (Tostran) in post-menopausal women can be found here.
Formulary assessment tool: estradiol spray (Lenzetto)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The formulary assessment tool for estradiol spray (Lenzetto) can be found here.
Formulary assessment tool: Dacepton (apomorphine)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The formulary assessment tool for Dacepton (apomorphine) can be found here.
Formulary assessment tool: estradiol/progesterone (Bijuve) for HRT
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The formulary assessment tool for estradiol/progesterone (Bijuve) for HRT can be found here.
March Newsletter
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition covers RDTC publications produced in the last financial year, specials added to new Part VIIID section of the Drug Tariff, a spotlight on Hidradenitis suppurativa, the potential contamination of infant formula food products, unintentional paracetamol overdose in adult inpatients with low bodyweight, updates to the routine immunisation schedule, and resources relating to Ramadan.
New publication type: formulary assessment tools
Our new series of monthly formulary amendments have been well received, so we’ve added another set of support documents: formulary assessment tools. These are templates to support local decision making, bringing together NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The first publications in the series cover levomepromazine 6mg tablets and indapamide 1.5mg modified release tablets. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Find all of our formulary tools at their own formulary support tools landing page.
Annual Horizon Scanning Report – 2022-2023
Each year the RDTC considers the information published in the SPS Prescribing Outlook series, and from this information highlights developments that are likely to have significant impact on primary care prescribing budgets, over the coming 12 – 15 months.
The RDTC takes the SPS Cost Calculator and aids in filters to calculate totals for each of its stakeholder ICS and CCGs.
A Key Considerations Document accompanies the Cost Calculator detailing the key messages, summarising the current prescribing budget position, and suggesting proposed uplifts to prescribing budgets for the next financial year.
This is supplemented throughout the year with the RDTC Monthly Horizon Scanning series, which provides a more accurate monthly account of the impact of new medicines and recommendations as they publish.
There are five regional versions of this publication. These can all be found on the Annual Horizon Scanning Report page